Systemic lupus erythematosus

Systemic autoimmune disease affecting skin, joints, kidneys, CNS, and serosa. Foundation: hydroxychloroquine in all patients; immunosuppressants and biologics added by severity.

ICD-10 M321 drug

Also known as: SLE

Drugs used for this condition

AHydroxychloroquineFirst line · Antimalarials, aminoquinolinesFoundation therapy for all SLE patients regardless of severity per EULAR 2023, ACR 2024, BSR 2018. Reduces flare frequency, organ damage, thromboembolic events, and all-cause mortality – the only drug with demonstrated benefit on long-term SLE outcomes. Dose 200–400 mg/day, not exceeding 5 mg/kg ideal body weight to prevent retinopathy. Effect develops over 3–6 months. Ophthalmologic exam at baseline, after 5 years, then annually.

How to read tiers A–F

Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit